Literature DB >> 19773175

2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.

Kerstin Sander1, Tim Kottke, Yusuf Tanrikulu, Ewgenij Proschak, Lilia Weizel, Erich H Schneider, Roland Seifert, Gisbert Schneider, Holger Stark.   

Abstract

The human histamine H(4) receptor (hH(4)R) is a promising new target in the therapy of inflammatory diseases and disorders of the immune system. For the development of new H(4)R antagonists a broad ligand-based virtual screening was performed resulting in two hits. The dissection of their common annelated aromatic core into its heteromonocyclic components showed that 2,4-diaminopyrimidine is a potent hH(4)R affinity scaffold, which was comprehensively investigated. Structure-activity relationship studies revealed that slight structural changes evoke extensive differences in functional activities and potencies: while o- and p-substituted benzyl amines mainly showed partial agonism, m-substituted and rigidified ones exhibited inverse agonist efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773175     DOI: 10.1016/j.bmc.2009.08.059

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  19 in total

1.  Studies of H4R antagonists using 3D-QSAR, molecular docking and molecular dynamics.

Authors:  Jing Liu; Yan Li; Hui-Xiao Zhang; Shu-Wei Zhang; Ling Yang
Journal:  J Mol Model       Date:  2011-06-07       Impact factor: 1.810

2.  A search for functional histamine H4 receptors in the human, guinea pig and mouse brain.

Authors:  Monika Feliszek; Valerie Speckmann; Daniel Schacht; Marec von Lehe; Holger Stark; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-10       Impact factor: 3.000

3.  Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase.

Authors:  Oleg A Volkov; Anthony J Brockway; Stephen A Wring; Michael Peel; Zhe Chen; Margaret A Phillips; Jef K De Brabander
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

Review 4.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Differential effects of functionally different histamine H4 receptor ligands on acute irritant dermatitis in mice.

Authors:  Maristella Adami; Cristina Micheloni; Daniela Grandi; Holger Stark
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-25       Impact factor: 3.000

6.  Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.

Authors:  S Nijmeijer; H Engelhardt; S Schultes; A C van de Stolpe; V Lusink; C de Graaf; M Wijtmans; E E J Haaksma; I J P de Esch; K Stachurski; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

7.  The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages.

Authors:  Susanne Mommert; Lisanne Ratz; Holger Stark; Ralf Gutzmer; Thomas Werfel
Journal:  Inflamm Res       Date:  2018-03-29       Impact factor: 4.575

8.  Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity.

Authors:  Eva Wagner; Hans-Joachim Wittmann; Sigurd Elz; Andrea Strasser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-17       Impact factor: 3.000

9.  Profiling of histamine H4 receptor agonists in native human monocytes.

Authors:  M Gschwandtner; B Koether; T Werfel; H Stark; R Gutzmer
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  DOGS: reaction-driven de novo design of bioactive compounds.

Authors:  Markus Hartenfeller; Heiko Zettl; Miriam Walter; Matthias Rupp; Felix Reisen; Ewgenij Proschak; Sascha Weggen; Holger Stark; Gisbert Schneider
Journal:  PLoS Comput Biol       Date:  2012-02-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.